Investing in Stocks Made Easy!
at ₹0 Brokerage with 5paisa.
+91
By proceeding, you agree to all T&C*
Investing in Stocks Made Easy!
We've sent a 6-digit verification code to +91 99123918232
Didn't receive the code? Resend
NEPHROCARE

Nephro Care India Share Price

 

 

Nephro Care India live price: ₹79.75. It opened at ₹85 vs previous close ₹89; intraday high/low: ₹85/₹77. The 50 & 200 DMA stand at ₹80.67/₹113.04.

Nephro Care India Performance

  • Today's Low
  • ₹77
  • Today's High
  • ₹85
  • 52 Week Low
  • ₹50
  • 52 Week High
  • ₹183
  • Open Price₹85
  • Previous Close₹89
  • Volume44,800
  • 50 DMA₹80.67
  • 100 DMA₹91.79
  • 200 DMA₹113.04

Nephro Care India Chart

Investment Returns

  • Over 1 Month + 52.49%
  • Over 3 Month -18.62%
  • Over 6 Month -42%
  • Over 1 Year -44.04%

Smart Investing Starts Here Start SIP with Nephro Care India for Steady Growth!

Invest Now

Nephro Care India Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 36.1
  • PEG Ratio
  • -
  • Market Cap Cr
  • 132
  • P/B Ratio
  • 2.4
  • Average True Range
  • 5.83
  • EPS
  • 1.74
  • Dividend Yield
  • 0
  • MACD Signal
  • 3.51
  • RSI
  • 50.92
  • MFI
  • 49.25

Nephro Care India Financials

Nephro Care India Technicals

EMA & SMA

Current Price
₹79.75
-8.85 (-9.99%)
pointer
  • Bearish Moving Average 12
  • Bullish Moving Average 4
  • 20 Day
  • ₹80.30
  • 50 Day
  • ₹80.67
  • 100 Day
  • ₹91.79
  • 200 Day
  • ₹113.04

Resistance and Support

80.6 Pivot Speed
  • R3 91.50
  • R2 88.15
  • R1 83.95
  • S1 76.40
  • S2 73.05
  • S3 68.85

Ratings

Master Rating

EPS Strenth

N/A

Price Strength

Buyer Demand

Group Rank

Nephro Care India Ltd has an operating revenue of Rs. 108.02 Cr. on a trailing 12-month basis. An annual revenue growth of 72% is outstanding, Pre-tax margin of 10% is healthy, ROE of 6% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and around 15% up from its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 9 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 85 indicates it belongs to a poor industry group of Medical-Hospitals and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Nephro Care India Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-13 Quarterly Results & Others To consider other business matters.
2025-11-12 Quarterly Results & Others To consider other business matters.
2025-07-10 Others To consider other business matters.
2025-05-28 Audited Results & Others To consider other business matters.
2025-02-12 Others To consider other business matters

Nephro Care India Shareholding Pattern

61.71%
0.73%
30.33%
7.23%

Nephro Care India FAQs

Nephro Care India share price is ₹79 As on 30 April, 2026 | 23:37

The Market Cap of Nephro Care India is ₹131.5 Cr As on 30 April, 2026 | 23:37

The P/E ratio of Nephro Care India is 36.1 As on 30 April, 2026 | 23:37

The PB ratio of Nephro Care India is 2.4 As on 30 April, 2026 | 23:37

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23